慢性阻塞性肺疾病%复方异丙托溴铵气雾剂%糜蛋白酶%雾化吸入治疗
慢性阻塞性肺疾病%複方異丙託溴銨氣霧劑%糜蛋白酶%霧化吸入治療
만성조새성폐질병%복방이병탁추안기무제%미단백매%무화흡입치료
Chronic obstructive pulmonary disease%Combivent%Alpha-chymotrypsin%Inhalation therapy
目的 了解复方异丙托溴铵气雾剂、糜蛋白酶两种药物雾化吸入治疗稳定期慢性阻塞性肺疾病(COPD)患者肺功能改善情况.方法 150例COPD患者按COPD级别、年龄,综合考虑患者吸烟状况及其他影响肺功能损害的合并症、并发症等统一排序.依据患者的序列号/3的余数将患者分为3组:复方异丙托溴铵气雾剂组,糜蛋白酶组,对照组,每组均50例.对每位患者分别给予连续5d,每日上、下午各1次雾化吸入治疗,在首次雾化前及末次雾化后分别进行肺功能及血气分析检查,分析3组相关指标用力肺活量(FVC)、1秒钟用力呼气量(FEV1％)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、动脉血氧饱和度(SaO2).结果雾化前后复方异丙托溴铵气雾剂组FVC[ (69±17)％、(74±15)％,t=-4.223,P＜0.01]、FEV1％ [(68±21)％、(71±20)％,t=-2.777,P ＜0.01]、PaO2[ (74 ±7)、(76 ±6)mm Hg,t=-11.201,P＜0.01]、PaCO2[ (40±3)、(39±2)mm Hg,t=3.888,P＜0.01]、SaO2[ (94.4±1.7)％、(94.9±1.1)％,t=- 4.452,P＜0.01],糜蛋白酶组FVC[ (66±13)％、(70±14)％,t=- 32.375,P=0.022]、FEV1％[ (63±13)％、(66±15)％,t=-2.229,P =0.030]、PaO2[(72±8)、(76±6)mm Hg,t=- 18.763,P＜0.01]、PaCO2[ (40±3)、(38 ±2)mm Hg,t =6.137,P ＜0.01]、SaO2[ (94.0±1.8)％、(95.0±1.3)％,t=-9.339,P＜0.01],差异均有统计学意义.结论 复方异丙托溴铵气雾剂及糜蛋白酶雾化吸入治疗均可明显改善COPD患者肺功能.
目的 瞭解複方異丙託溴銨氣霧劑、糜蛋白酶兩種藥物霧化吸入治療穩定期慢性阻塞性肺疾病(COPD)患者肺功能改善情況.方法 150例COPD患者按COPD級彆、年齡,綜閤攷慮患者吸煙狀況及其他影響肺功能損害的閤併癥、併髮癥等統一排序.依據患者的序列號/3的餘數將患者分為3組:複方異丙託溴銨氣霧劑組,糜蛋白酶組,對照組,每組均50例.對每位患者分彆給予連續5d,每日上、下午各1次霧化吸入治療,在首次霧化前及末次霧化後分彆進行肺功能及血氣分析檢查,分析3組相關指標用力肺活量(FVC)、1秒鐘用力呼氣量(FEV1％)、動脈血氧分壓(PaO2)、動脈血二氧化碳分壓(PaCO2)、動脈血氧飽和度(SaO2).結果霧化前後複方異丙託溴銨氣霧劑組FVC[ (69±17)％、(74±15)％,t=-4.223,P＜0.01]、FEV1％ [(68±21)％、(71±20)％,t=-2.777,P ＜0.01]、PaO2[ (74 ±7)、(76 ±6)mm Hg,t=-11.201,P＜0.01]、PaCO2[ (40±3)、(39±2)mm Hg,t=3.888,P＜0.01]、SaO2[ (94.4±1.7)％、(94.9±1.1)％,t=- 4.452,P＜0.01],糜蛋白酶組FVC[ (66±13)％、(70±14)％,t=- 32.375,P=0.022]、FEV1％[ (63±13)％、(66±15)％,t=-2.229,P =0.030]、PaO2[(72±8)、(76±6)mm Hg,t=- 18.763,P＜0.01]、PaCO2[ (40±3)、(38 ±2)mm Hg,t =6.137,P ＜0.01]、SaO2[ (94.0±1.8)％、(95.0±1.3)％,t=-9.339,P＜0.01],差異均有統計學意義.結論 複方異丙託溴銨氣霧劑及糜蛋白酶霧化吸入治療均可明顯改善COPD患者肺功能.
목적 료해복방이병탁추안기무제、미단백매량충약물무화흡입치료은정기만성조새성폐질병(COPD)환자폐공능개선정황.방법 150례COPD환자안COPD급별、년령,종합고필환자흡연상황급기타영향폐공능손해적합병증、병발증등통일배서.의거환자적서렬호/3적여수장환자분위3조:복방이병탁추안기무제조,미단백매조,대조조,매조균50례.대매위환자분별급여련속5d,매일상、하오각1차무화흡입치료,재수차무화전급말차무화후분별진행폐공능급혈기분석검사,분석3조상관지표용력폐활량(FVC)、1초종용력호기량(FEV1％)、동맥혈양분압(PaO2)、동맥혈이양화탄분압(PaCO2)、동맥혈양포화도(SaO2).결과무화전후복방이병탁추안기무제조FVC[ (69±17)％、(74±15)％,t=-4.223,P＜0.01]、FEV1％ [(68±21)％、(71±20)％,t=-2.777,P ＜0.01]、PaO2[ (74 ±7)、(76 ±6)mm Hg,t=-11.201,P＜0.01]、PaCO2[ (40±3)、(39±2)mm Hg,t=3.888,P＜0.01]、SaO2[ (94.4±1.7)％、(94.9±1.1)％,t=- 4.452,P＜0.01],미단백매조FVC[ (66±13)％、(70±14)％,t=- 32.375,P=0.022]、FEV1％[ (63±13)％、(66±15)％,t=-2.229,P =0.030]、PaO2[(72±8)、(76±6)mm Hg,t=- 18.763,P＜0.01]、PaCO2[ (40±3)、(38 ±2)mm Hg,t =6.137,P ＜0.01]、SaO2[ (94.0±1.8)％、(95.0±1.3)％,t=-9.339,P＜0.01],차이균유통계학의의.결론 복방이병탁추안기무제급미단백매무화흡입치료균가명현개선COPD환자폐공능.
Objective To investigate the effect of combivent and alpha-chymotrypsin inhalants on the improvement of lung function in patients with chronic obstructive pulmonary disease (COPD).Methods One hundred and fifty patients with COPD were ranked in the order of COPD severity and a comprehensive evaluation of age,smoking status and other complications which may have effects on lung function.According to the rank of the patients,they were classified into three groups (combivent,alpha-chymotrypsin and control groups) according to remainder after their ranking numbers were divided by three.Each patient was given treatment two times ( one in the morning and one in the afternoon) for 5 consecutive days.Lung function and blood gas were detected before first spray atomization and after last treatment.The parameters such as forced vital capacity (FVC),Forced expiratory volume in one second (FEV1％),arterial oxygen pressure (PaO2 ),arterial carbon dioxide partial pressure ( PaCO2 ),arterial oxygen saturation (SaO2 ) were compared.Results In the combivent group,the parameters before and after treatment were:FVC[(69 ±17)％,(74±15)％,t =-4.223,P＜0.O1],FEV1％ [(68±21)％,(71 ±20)％,t=-2.777,P=0.008],PaO2[(74±7),(76±6)mmHg,t=-11.201,P＜0.01],PaCO2[(40±3),(39±2)mm Hg,t=3.888,P＜0.01],SaO2[(94.4±1.7)％,(94.9±1.1)％,t=-4.452,P ＜0.01 ].In the alpha-chymotrypsin group,the parameters before and after treatment were:FVC[ (66 ±13)％,(70±14)％,t=-32.375,P=0.022],FEV1％ [(63±13)％,(66±15)％,t=-2.229,P=0.030],PaO2[(72±8),(76±6)mmHg,t=-18.763,P＜0.01],PaCO2[(40±3),(38±2)mmHg,t=6.137,P＜0.01],SaO2[(94.0±1.8)％,(95.0±1.3)％,t=-9.339,P＜0.001.Conclusion Combivent and alpha-chymotrypsin inhalants are both effective to improve the lung function of patients with COPD.
